Effective long-term temozolomide rechallenge in a macroprolactinoma

about

Effective long-term temozolomide rechallenge in a macroprolactinoma

Item

http://www.wikidata.org/entity/Q57299913

description

scientific article published on 25 September 2018

@en

wetenschappelijk artikel

@nl

наукова стаття, опублікована у вересні 2018

@uk

name

Effective long-term temozolomide rechallenge in a macroprolactinoma

@en

Effective long-term temozolomide rechallenge in a macroprolactinoma

@nl

type

Item

label

Effective long-term temozolomide rechallenge in a macroprolactinoma

@en

Effective long-term temozolomide rechallenge in a macroprolactinoma

@nl

prefLabel

Effective long-term temozolomide rechallenge in a macroprolactinoma

@en

Effective long-term temozolomide rechallenge in a macroprolactinoma

@nl

P1476

Effective long-term temozolomide rechallenge in a macroprolactinoma

@en

P2093

Antonio Silvani

http://www.w3.org/2001/XMLSchema#string

Benedetta Zampetti

http://www.w3.org/2001/XMLSchema#string

Giorgia Simonetti

http://www.w3.org/2001/XMLSchema#string

Renato Cozzi

http://www.w3.org/2001/XMLSchema#string

P2860

Temozolomide treatment for aggressive pituitary tumors: correlation of clinical outcome with O(6)-methylguanine methyltransferase (MGMT) promoter methylation and expression

Advances in the treatment of prolactinomas.

Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline.

Temozolomide in the management of dopamine agonist-resistant prolactinomas.

Temozolomide treatment can improve overall survival in aggressive pituitary tumors and pituitary carcinomas.

Temozolomide therapy for resistant prolactin-secreting pituitary adenomas and carcinomas: a systematic review.

Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience.

Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas.

European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas.

Treatment of aggressive pituitary tumours and carcinomas: Results of a European Society of Endocrinology (ESE) survey 2016.

P31

scholarly article

P356

10.1530/EDM-18-0092

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

2018

http://www.w3.org/2001/XMLSchema#string

P50

Roberto Attanasio

P577

2018-09-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30306786

http://www.w3.org/2001/XMLSchema#string

P932

6169538

http://www.w3.org/2001/XMLSchema#string